Drug Profile
Tocilizumab biosimilar - Outlook Therapeutics
Alternative Names: ONS-3030Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Outlook Therapeutics
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ankylosing spondylitis; Chronic lymphocytic leukaemia; Crohn's disease; Dermatomyositis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Multiple myeloma; Pancreatic cancer; Polymyositis; Rheumatoid arthritis
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Ankylosing spondylitis in USA (IV) (Outlook Therapeutics pipeline, September 2023)
- 04 Sep 2023 Discontinued - Preclinical for Chronic lymphocytic leukaemia in USA (IV) (Outlook Therapeutics pipeline, September 2023)
- 04 Sep 2023 Discontinued - Preclinical for Crohn's disease in USA (IV) (Outlook Therapeutics pipeline, September 2023)